This bias is reinforced by the marketing message of pharmaceutical companies to physicians, which has emphasized research on delayed diagnosis and under-recognition of bipolar disorder, possibly sensitizing clinicians accordingly.
La campaña contra el sub-reconocimiento probablemente ha hecho que se diagnostique erróneamente con desorden bipolar a pacientes deprimidos ansiosos, agitados y/o irritables que se quejan de insomnio y “pensamientos incontrolables”.